Abilify 10 mg Tablets (Abilify 10mg Bottle Label)
Abilify Tablet
Product Images NDC 59148-011
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Abilify (NDC 59148-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Otsuka America Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Abilify 15 mg Tablets (Abilify 15mg Bottle Label)
Abilify 20 mg Tablets (Abilify 20mg Bottle Label)
Ablify 2 mg Tablets (Abilify 2mg Bottle Label)
Abilify 30 mg Tablets (Abilify 30mg Bottle Label)
Abilify 5 mg Tablets (Abilify 5mg Bottle Label)
Chemical Structure (Abilify Chem Structure)
Not available.*
Figure 1 (Abilify Figure 01)
This text provides a table that shows the effect of different drugs on Abilify, by listing their PK (pharmacokinetics) and how they impact the drug's concentration in the body. The drugs are categorized based on their inhibition or induction of certain enzymes, like CYP2D6, that affect Abilify. Some examples of drugs listed are ketoconazole as a CYP3A4 inhibitor and famotidine as a gastric acid blocker. The table also shows the change in Abilify concentration relative to the reference concentration without the interacting drug.*
Figure 2 (Abilify Figure 02)
The text seems to describe a chart or graph showing the effect of other drugs on Abilify, and lists various drugs that could have an impact, including reoonazoe, quindre Qv, catanazpre AU, and some others. The chart also includes a measure called Dehydro-Arpprazo Foi Change and 90% C1, which is plotted on a scale. Unfortunately, without more context it's difficult to provide a more detailed or useful description.*
Figure 3 (Abilify Figure 03)
This appears to be a table or graph displaying the effect of Abilify on other drugs. The table displays the PK Fold Change and 90% CI values for different drugs such as deopreborpran, zere, Roarfarn, oneprazoe, UGT1A4, Enetine, wprose, Kz, nlfasine, wnaine, Odesmetyhena, snetyhenitoine, and esciopram. However, due to the unclear and incomplete text, the information is not fully available.*
Figure 4 (Abilify Figure 04)
This is a study with information about special populations with emphasis on gender, age, and liver and kidney impairment in relation to the drug Avipiprazole. The study shows dose changes and 90% confidence intervals.*
Figure 5 (Abilify Figure 05)
Figure 6 (Abilify Figure 06)
This text seems to be a table showing data on the proportion of relapse and the number of subjects at risk for Abilify and Placebo. The table displays the number of subjects at risk for both Abilify and Placebo, the proportion with relapse, and the number of days from randomization. Without more context, it is difficult to provide a specific use for this data.*
Figure 7 (Abilify Figure 07)
This appears to be a graph that compares the proportion with relapse for ABILIFY versus PLACEBO over the course of 182 days using a sample size of 83 subjects. The graph shows the proportion increasing for both ABILIFY and PLACEBO over time, with ABILIFY having a lower proportion of relapse compared to PLACEBO. The x-axis represents the number of days from randomization and the y-axis represents the proportion with relapse.*
Figure 8 (Abilify Figure 08)
This appears to be a table showing the proportion with relapse, number of subjects at risk, and days from randomization for the drug ABILIFY and placebo. The data seems to be broken down into different time intervals. There is not enough context to determine the purpose or relevance of this data.*
Figure 9 (Abilify Figure 09)
This text represents a graph that shows the least-squares mean change in YGTSS Total TIC Score over time with different treatments from baseline. The treatments are Abilify Low and Abilify High compared to a placebo. The X-axis shows the weeks of treatment, and the Y-axis displays the change in the YGTSS Total TIC Score.*
Abilify Injection For Intramuscular Use Only (PDP)
The text seems to describe medication called "aripiprazole" in the form of an injection that comes in a 75mg dose. It also mentions the dispensing of a medication guide. The remaining text seems to be illegible characters and not understandable.*
Abilify 10-mg Orally Disintegrating Tablets (PDP)
ABILIFY DISCMELT* 10 mg is an Orally Disintegrating Tablet of aripiprazole used for the treatment of several mental illnesses. This medication is manufactured by Otsuka America Pharmaceutical Inc. and should be taken as directed in the medication guide.*
Abilify 15-mg Orally Disintegrating Tablets (PDP)
ABILIFY DISCMELT is a medication available in orally disintegrating tablets of 15 mg and 18 mg of aripiprazole, manufactured by Otsuka America Pharmaceutical Inc. Dispensation of this medication requires a medication guide. The text includes some numerical values, but their meaning is not specified.*
Abilify Oral Solution 1mg/ml (PDP)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
